Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lopinavir/Ritonavir Tablet vs Soft Gel Capsule and QD vs BID in HIV-1
NCT00262522Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Nov 2005
- Primary completion
- Jul 2008
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of lopinavir + ritonavir in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by Abbott Laboratories. Primary endpoints: Percentage of Subjects With Adverse Events of Diarrhea During the First 8 Weeks and Percentage of Subjects With Plasma HIV-1 RNA Levels < 50 Copies/mL at Week 48. Started Nov 2005; status: completed.
02
Drugs
lopinavir + ritonavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00262522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262522.